Shanghai - Delayed Quote CNY

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (688621.SS)

50.59
+5.64
+(12.55%)
At close: 3:00:03 PM GMT+8
Loading Chart for 688621.SS
  • Previous Close 44.95
  • Open 44.92
  • Bid 50.59 x --
  • Ask 50.60 x --
  • Day's Range 44.92 - 53.94
  • 52 Week Range 28.90 - 53.94
  • Volume 11,744,544
  • Avg. Volume 3,555,700
  • Market Cap (intraday) 5.666B
  • Beta (5Y Monthly) 0.22
  • PE Ratio (TTM) 42.51
  • EPS (TTM) 1.19
  • Earnings Date --
  • Forward Dividend & Yield 0.17 (0.37%)
  • Ex-Dividend Date Jul 9, 2024
  • 1y Target Est --

Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of drugs in China. The company operates external preparation platform that focuses on the research and development of new drugs and generic drugs for skin external preparations; children's clinical data bridging research center; pediatric drug research and development platform; pediatric drug delivery dosage research and development platform; respiratory tract drug delivery and topical preparation platforms; polypeptide and other drug molecular design and development platform; genotoxic impurity detection platform; technology platform for slow and controlled release preparations; drug synthesis platform; and synthesis technology platform. It also offers SMO, clinical quality management, data management and statistical analysis, project management, test center, clinical research center, clinical trials, TMFDocument management, quality control, Medical Writing, medical monitoring, and pharmacovigilance services; and registration-related services for chemical drugs, biological products, and medical device products. In addition, the company operates quantitative pharmacology platform that use technology on pharmacokinetics, pharmacodynamics, body function, disease mechanism and test process, and other information for quantitative research; and mass spectrometry, immunological analysis, cell biology, and molecular biology platforms that provide biological analysis services for large and small molecular drugs, as well as operates as a Contract Research Organization for Professional Peptide Drug Research and Development. Beijing Sun-Novo Pharmaceutical Research Co., Ltd. was founded in 2009 and is based in Beijing, China.

www.sun-novo.com

1,556

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 688621.SS

View More

Performance Overview: 688621.SS

Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

688621.SS
34.19%
SSE Composite Index (000001.SS)
0.10%

1-Year Return

688621.SS
0.18%
SSE Composite Index (000001.SS)
7.44%

3-Year Return

688621.SS
24.23%
SSE Composite Index (000001.SS)
6.40%

5-Year Return

688621.SS
45.93%
SSE Composite Index (000001.SS)
19.00%

Compare To: 688621.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 688621.SS

View More

Valuation Measures

Annual
As of 5/22/2025
  • Market Cap

    5.03B

  • Enterprise Value

    4.98B

  • Trailing P/E

    37.77

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.77

  • Price/Book (mrq)

    4.89

  • Enterprise Value/Revenue

    4.71

  • Enterprise Value/EBITDA

    35.56

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    12.70%

  • Return on Assets (ttm)

    3.80%

  • Return on Equity (ttm)

    12.54%

  • Revenue (ttm)

    1.06B

  • Net Income Avi to Common (ttm)

    134.23M

  • Diluted EPS (ttm)

    1.19

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    670.58M

  • Total Debt/Equity (mrq)

    60.13%

  • Levered Free Cash Flow (ttm)

    -8.12M

Research Analysis: 688621.SS

View More

Company Insights: 688621.SS

Research Reports: 688621.SS

View More

People Also Watch